School of Medicine
Showing 211-220 of 243 Results
-
Laurens van de Wiel
Postdoctoral Scholar, Cardiovascular Medicine
BioI am a post-doctoral researcher at Stanford University under supervision of Matthew Wheeler and Stephen Montgomery. My research focuses on understanding the entire spectrum of genetic variation effects on protein function and structure in order to decipher molecular mechanisms of disease.
My post-doctoral work centers on developing novel software methodologies which combine multi-omics data to interpret the functional impact of genetic variants in undiagnosed patients. I am part of the Undiagnosed Disease Network (UDN) at Stanford Center for Undiagnosed Diseases (CUD), Genomics Research to Elucidate the Genetics of Rare Diseases (GREGoR) consortium at GREGoR Stanford Site (GSS), and the Molecular Transducers of Physical Activity Consortium (MoTrPAC) at the Bioinformatics Center (BIC).
Before joining Stanford. I was received my Ph.D. in 2021 at the Radboud University Medical Center under supervision of Christian Gilissen, Gert Vriend, and Joris Veltman. I received my MSc degree in 2014 at Radboud University under supervision of Tom Heskes, Evgeni Levin, and Armand Paauw. Before my Ph.D, I worked as a Data Scientist at FLXone, where I developed machine learning solutions within a large-scale, real-time infrastructure.
Research
I am interested in a variety of topics in Bioinformatics and Computer Science. In particular, I am interested in the application of Artificial Intelligence and Statistical Modelling to analyse human (Rare) Mendelian Disease Genetics, Evolutionary Comparative Genomics, Protein Domain Homology, and Molecular Structures. -
Anubodh Sunny Varshney
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Anubodh Sunny Varshney is a Clinical Assistant Professor, Medical Director of Mechanical Circulatory Support, and Associate Director of the Fellowship Program in the Section of Advanced Heart Failure, Transplant Cardiology, and Mechanical Circulatory Support at Stanford. In addition to caring for patients with advanced heart disease, he is also a clinical researcher and works to identify patient groups that have sub-optimal outcomes with current therapies, define benchmark outcomes that next generation therapies should improve upon, and understand factors that influence adoption of novel drug and device therapies for cardiovascular disease.
Dr. Varshney earned a BS in biomedical engineering from Washington University in St. Louis and an MD from the University of Texas Southwestern Medical School. He completed residency in Internal Medicine and fellowship in Cardiovascular Medicine at Brigham & Women’s Hospital/Harvard Medical School and fellowship in Advanced Heart Failure, Transplant Cardiology, and Mechanical Circulatory Support at Stanford University.
Dr. Varshney also has experience advising multiple medical device, drug, and digital health start-ups and currently serves as a Venture Advisor at Broadview Ventures, a philanthropically-funded, mission-driven investment organization that invests in early-stage companies developing technologies that have the potential to improve outcomes for patients with cardiovascular disease or stroke. -
Paul J. Wang, MD
John R. and Ai Giak L. Singleton Director, Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Bioengineering
Current Research and Scholarly InterestsDr. Wang's research centers on the development of innovative approaches to the treatment of arrhythmias, including more effective catheter ablation techniques, more reliable implantable devices, and less invasive treatments. Dr. Wang's clinical research interests include atrial fibrillation, ventricular tachycardia, syncope, and hypertrophic cardiomyopathy. Dr. Wang is committed to addressing disparities in care and is actively involved in increasing diversity in clinical trials.
-
Chad S. Weldy, M.D., Ph.D.
Instructor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsAs a physician-scientist I work to understand the genetic basis of cardiovascular disease and the transcriptional and epigenomic mechanisms of atherosclerosis. My work is focused across four main areas of cardiovascular genetics and mechanisms of coronary artery disease and smooth muscle biology:
1.Vascular smooth muscle specific ADAR1 mediated RNA editing of double stranded RNA and activation of the double stranded RNA receptor MDA5 in coronary artery disease and vascular calcification
2.Defining on single cell resolution the cellular and epigenomic features of human vascular disease across vascular beds of differing embryonic origin
3.CRISPRi screening with targeted perturb seq (TAPseq) to identify novel CAD genes in human coronary artery smooth muscle cells
4.Investigation of the epigenetic and molecular basis of coronary artery disease and smooth muscle cell transition in mice with conditional smooth muscle genetic deletion of CAD genes Pdgfd and Sox9
My work is focused on discovery of causal mechanisms of disease through leveraging human genetics with sophisticated molecular biology, single cell sequencing technologies, and mouse models of disease. This work attempts to apply multiple scientific research arms to ultimately lead to novel understandings of vascular disease and discover important new therapeutic approaches for drug discovery.
First Author Manuscripts for this work:
•Weldy, C. S., et al. (2025). Smooth muscle cell expression of RNA editing enzyme ADAR1 controls activation of RNA sensor MDA5 in atherosclerosis. (2025). Nature Cardiovascular Research. 1-17, PMID: 40958051, doi: 10.1038/s44161-025-00710-5
•*Selected as finalist for Louis N. and Arnold M. Katz Basic Science Research Prize from the American Heart Association, finalist competition November 16, 2024, Chicago
•Work was highlighted in the Stanford Department of Medicine News
https://medicine.stanford.edu/news/current-news/standard-news/RNA-editing.html
•Weldy, C.S., et al. (2025). Epigenomic landscape of single vascular cells reflects developmental origin and disease risk loci. Molecular Systems Biology. 1-25, PMID: 40931195, doi:10.1038/s44320-025-00140-2.
•*Selected for the cover of November 2025 edition of Molecular Systems Biology
Grant funding received for this work:
Mentored Clinical Scientist Research Career Development Award (K08)(NIH/NHLBI, 1 K08 HL167699-01), August, 2023 – July 2028. PI: Weldy, Chad
•Title of proposal: “ADAR Mediated RNA editing is a causal mechanism in coronary artery disease”.
•Activated 08/01/2023
•$850,000 over 5 years
Career Development Award, American Heart Association (AHA CDA)(23CDA1042900), July, 2023 – June, 2026. PI: Weldy, Chad
•Title of proposal: “Linking RNA editing to coronary artery calcification and disease”
•Activated 07/01/2023
•$231,000 over three years
NIH Loan Repayment Program (LRP) Award (NIH/NHLBI) Renewal Award, July, 2023. PI: Weldy, Chad
•Title of proposal: “RNA editing is a causal mechanism of coronary artery disease”
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32) (NIH/NHLBI, 1 F32 HL160067-01), July, 2021 – June 2023 (Completed). PI: Weldy, Chad
• Titled, “A transcriptional network which governs smooth muscle transition is mediated by causal coronary artery disease gene PDGFD”
•*Received perfect score with impact score 10, 1st percentile
NIH Loan Repayment Program (LRP) Award (NIH/NHLBI), July, 2021. PI: Weldy, Chad
•Title of proposal: "Single cell transcriptomic and epigenomic features of human atherosclerosis".
•This will award up to $100,000 towards student loans over the next 24 months with opportunity for renewal after 24 months. -
Matthew T. Wheeler
Associate Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsTranslational research in rare and undiagnosed diseases. Basic and clinical research in cardiomyopathy genetics, mechanisms, screening, and treatment. Investigating novel agents for treatment of hypertrophic cardiomyopathy and new mechanisms in heart failure. Cardiovascular screening and genetics in competitive athletes, disease gene discovery in cardiomyopathy and rare disease. Informatics approaches to rare disease and multiomics. Molecular transducers of physical activity bioinformatics.
